Kamran Alam is CFO at Taysha Gene Therapies, Inc. (TSHA). They have made 5 open-market trades across 2 companies since 2015, most recently 2026-02-04.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TSHA | 1,442,131 | $5.2M |
| AQXP | 29,079 | $107K |
| Total | $5.3M |
Shares reported on the most recent Form 4, priced at the 2026-02-06 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TSHA | SELL | 2026-02-04 | 2026-02-06 | $4.52 | $7K | +3.7% | -0.6% | +44.4% |
| TSHA | SELL | 2026-01-23 | 2026-01-27 | $4.72 | $485K | -2.7% | -3.6% | +36.3% |
| TSHA | SELL | 2025-08-21 | 2025-08-22 | $2.85 | $311K | +9.4% | -3.7% | +33.9% |
| TSHA | SELL · 10b5-1 | 2023-08-24 | 2023-08-25 | $2.33 | $77K | +64.9% | +33.3% | -14.9% |
| TSHA | SELL · 10b5-1 | 2022-08-23 | 2022-08-24 | $3.47 | $12K | -16.8% | -48.9% | -39.2% |
| TSHA | SELL · 10b5-1 | 2022-08-18 | 2022-08-22 | $3.70 | $106K | -6.1% | -34.0% | -35.5% |
| TSHA | SELL | 2021-08-18 | 2021-08-20 | $16.87 | $1.1M | +17.8% | +7.2% | -20.0% |
| AQXP | SELL | 2015-08-12 | 2015-08-14 | $18.67 | $543K | -35.3% | -0.6% | -0.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.